Time (h) | Subjects with moderate adverse reactions (n = 5) | Subjects without adverse reactions (n = 5) | ||
---|---|---|---|---|
vWf antigen | Factor VIII activity | vWf antigen | Factor VIII activity | |
Results are mean (95% confidence interval). In each subject, data were normalised to baseline values obtained before the start of the NAC infusion. | ||||
p<0.0001 and p = 0.0011 for adverse versus non-adverse reactions, and p = 0.025 and 0.46 for time with factor VIII and vWf, respectively (two way ANOVA). | ||||
Values in parentheses at 0 hours are baseline values [median, range] in kIU/l for factor VIII activity and vWf antigen. These values did not differ in subjects with and without adverse reactions (p = 0.68 for factor VIII and p = 0.73 for vWf; two tailed unpaired t test). | ||||
0 | 1 [0.72, 0.63–1.24] | 1 [0.95, 0.81–1.30] | 1 [1.06, 0.46–1.26] | 1 [1.01, 0.62–1.12] |
1 | 1.77 (0.83–2.71) | 1.85 (1.08–2.62) | 0.97 (0.87–1.08) | 1.00 (0.91–1.09) |
3 | 1.65 (0.70–2.59) | 1.76 (0.97–2.54) | 0.97 (0.94–1.00) | 1.06 (0.97–1.16) |
6 | 1.55 (0.77–2.33) | 1.71 (1.13–2.29) | 1.06 (0.95–1.18) | 1.24 (1.13–1.34) |
12 | 1.55 (0.87–2.23) | 1.63 (1.16–2.09) | 1.12 (0.97–1.27) | 1.23 (1.11–1.35) |
24 | 1.43 (0.95–1.90) | 1.44 (1.18–1.70) | 1.15 (0.97–1.33) | 1.21 (1.01–1.40) |
32 | 1.49 (1.00–1.98) | 1.47 (1.28–1.67) | 1.13 (0.85–1.42) | 1.21 (0.97–1.44) |
48 | 1.66 (1.18–2.14) | 1.35 (1.22–1.49) | 1.34 (1.11–1.57) | 1.22 (1.14–1.31) |
120 | 1.40 (1.14–1.66) | 1.35 (1.10–1.59) | 1.22 (0.97–1.28) | 1.18 (1.06–1.30) |